Presenter of 1 Presentation
O023 - BLOOD SERUM ATHEROGENICITY IN PATIENTS WITH SLE (ID 162)
Abstract
Background and Aims
Patients with systemic lupus erythematosus (SLE) are at high risk of atherosclerosis development. Serum atherogenicity, the ability of blood serum to induce intracellular cholesterol accumulation in cultured cells is a potential marker for cardiovascular risk assessment. The aim of this study was to estimate the association of serum atherogenicity of SLE patients with disease activity and corticosteroids (CS) administration.
Methods
Patients with systemic lupus erythematosus (SLE) are at high risk of atherosclerosis development. Serum atherogenicity, the ability of blood serum to induce intracellular cholesterol accumulation in cultured cells is a potential marker for cardiovascular risk assessment. The aim of this study was to estimate the association of serum atherogenicity of SLE patients with disease activity and corticosteroids (CS) administration.
Results
90% participants with SLE and only 15% of control participants possessed high atherogenic potential of blood serum. Serum atherogenicity in group without CS was higher than in group received CS (221±13% and 185±11% respectively, p=0.044). Serum atherogenicity correlated with SLEDAI index (r=0.82, p=0.04). No correlation was found between atherogenicity and blood lipids.
Conclusions
Serum atherogenicity is associated with disease activity in SLE patients that suggests the significance of immunological changes in pathogenesis of atherosclerosis. This work was supported by the Russian Science Foundation (Grant # 22-15-00198).